Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Inghirami

Showing results (171-180 of 239) with videos related to

Pageof 24
Sort By:
Blood|August 18, 2022
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilitiesLuca Vincenzo Cappelli, Danilo Fiore, Jude M Phillip, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Life Science Alliance|December 28, 2020
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progressionAndré F Rendeiro, Joseph Casano, Charles Kyriakos Vorkas, et al.
The Lancet. Oncology|May 17, 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trialUmberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, et al.
Cancer Cell|December 16, 2022
Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancerAnxo Martinez-Ordoñez, Angeles Duran, Marc Ruiz-Martinez, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2020
Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progressionAndré F Rendeiro, Joseph Casano, Charles Kyriakos Vorkas, et al.
Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.
Blood|February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCLJia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDSRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple MyelomaEugenio Morelli, Caroline Fidalgo Ribeiro, Silvia D Rodrigues, et al.
Pageof 24

Showing results (171-180 of 239) with videos related to

Sort By:
Pageof 24
Blood|August 18, 2022
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilitiesLuca Vincenzo Cappelli, Danilo Fiore, Jude M Phillip, et al.
Blood Advances|February 24, 2026
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, David A Bond, Bijal Shah, et al.
Life Science Alliance|December 28, 2020
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progressionAndré F Rendeiro, Joseph Casano, Charles Kyriakos Vorkas, et al.
The Lancet. Oncology|May 17, 2014
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trialUmberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, et al.
Cancer Cell|December 16, 2022
Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancerAnxo Martinez-Ordoñez, Angeles Duran, Marc Ruiz-Martinez, et al.
Medrxiv : the Preprint Server for Health Sciences|September 16, 2020
Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progressionAndré F Rendeiro, Joseph Casano, Charles Kyriakos Vorkas, et al.
Hematological Oncology|September 9, 2022
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma projectCarlos Chiattone, Monica Civallero, Thais Fischer, et al.
Blood|February 16, 2023
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCLJia Ruan, Alison Moskowitz, Neha Mehta-Shah, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDSRyan Nachman, Aleksandra Kopacz, Caitlin Unkenholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple MyelomaEugenio Morelli, Caroline Fidalgo Ribeiro, Silvia D Rodrigues, et al.
Pageof 24